{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-08T02:56:41.549153+00:00","company":{"ticker":"ORKA","cik":907654,"company_name":"Oruka Therapeutics, Inc."},"pagination":{"limit":100,"returned":16,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II LLC, and Oruka Therapeutics, Inc.","detail":"merger","count":1,"first_seen":"2024-04-03T23:59:59+00:00","last_seen":"2024-04-03T23:59:59+00:00","evidence_fact_ids":[63453]},{"display_name":"Lotus Church Ranch, LLC","detail":"lease","count":1,"first_seen":"2024-03-22T23:59:59+00:00","last_seen":"2024-03-22T23:59:59+00:00","evidence_fact_ids":[65513]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"ebafc0d8df58ec2491c71ed47ab23fd5af64b9ff","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2026-06-04T20:15:32+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis","proposal_type":"say_on_pay","results":[{"broker_non_votes":"1,267,194","subject":null,"votes_abstain":"73,091","votes_against":"875,114","votes_for":"43,033,967","votes_withheld":null}]},"claim":"Oruka Therapeutics, Inc. shareholders approved Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 3: Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis. The Company’s stockholders approved, by non-binding advisory vote, the compensation of our named executive officers as disclosed in the Proxy Statement. The tabulation of votes on this matter was as follows: Shares voted for: 43,033,967 Shares voted against: 875,114 Shares abstaining 73,091 There were 1,267,194 broker non-votes for this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-065294","anchor_url":"https://secwatch.observer/filing/0001213900-26-065294#claim-ebafc0d8df58ec2491c71ed47ab23fd5af64b9ff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390026065294/0001213900-26-065294-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0f3fe65b1d1ad9d08d80ffc53d0600eedde0fced","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2026-06-04T20:15:32+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Ratification of Independent Auditor Appointment","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"3,432","votes_against":"39,637","votes_for":"45,206,297","votes_withheld":null}]},"claim":"Oruka Therapeutics, Inc. shareholders approved Ratification of Independent Auditor Appointment at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 2: Ratification of Independent Auditor Appointment. The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. Shares voted for: 45,206,297 Shares voted against: 39,637 Shares abstaining 3,432 There were no broker non-votes for this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-065294","anchor_url":"https://secwatch.observer/filing/0001213900-26-065294#claim-0f3fe65b1d1ad9d08d80ffc53d0600eedde0fced","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390026065294/0001213900-26-065294-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7931620e9ac1a574cde2b1ada5744c9ea9db888c","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2026-06-04T20:15:32+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Election of Class II Directors","proposal_type":"director_election","results":[{"broker_non_votes":"1,267,194","subject":"Lawrence Klein","votes_abstain":null,"votes_against":null,"votes_for":"43,918,579","votes_withheld":"63,593"},{"broker_non_votes":"1,267,194","subject":"Chris Martin","votes_abstain":null,"votes_against":null,"votes_for":"43,936,173","votes_withheld":"45,999"}]},"claim":"Oruka Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 1: Election of Directors. The Company’s stockholders elected each of the two Class II directors proposed by the Company for election, to serve until the 2029 annual meeting of stockholders, and until their successors are elected and have qualified. The tabulation of votes on this matter was as follows: Director Nominee Shares Voted For Shares Withheld Lawrence Klein 43,918,579 63,593 Chris Martin 43,936,173 45,999 There were 1,267,194 broker non-votes for this proposal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-065294","anchor_url":"https://secwatch.observer/filing/0001213900-26-065294#claim-7931620e9ac1a574cde2b1ada5744c9ea9db888c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390026065294/0001213900-26-065294-index.htm"},{"fact_type":"equity_issuance","fact_key":"988255e84aaa57625a8a0fae954c37a14bfb7db6","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2025-09-22T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"purchase price of $14.999 per Pre-Funded Warrant","effective_date":"2025-09-19","item_codes_triggered":["3.02"],"purchaser":"certain institutional and accredited investors","security_type":"warrant","shares_text":"1,066,666 shares of Common Stock"},"claim":"Oruka Therapeutics, Inc. issued 1,066,666 shares of Common Stock of warrant to certain institutional and accredited investors for purchase price of $14.999 per Pre-Funded Warrant.","evidence_excerpt":"pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 1,066,666 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $14.999 per Pre-Funded Warrant","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-090129","anchor_url":"https://secwatch.observer/filing/0001213900-25-090129#claim-988255e84aaa57625a8a0fae954c37a14bfb7db6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390025090129/0001213900-25-090129-index.htm"},{"fact_type":"equity_issuance","fact_key":"8e4ac9287592b8215defdd83dbcf7b87f49134e3","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2025-09-22T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"price per share of $15.00","effective_date":"2025-09-19","item_codes_triggered":["3.02"],"purchaser":"certain institutional and accredited investors","security_type":"common_stock","shares_text":"10,933,405 shares"},"claim":"Oruka Therapeutics, Inc. issued 10,933,405 shares of common stock to certain institutional and accredited investors for price per share of $15.00.","evidence_excerpt":"an aggregate of 10,933,405 shares (the “Common Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price per share of $15.00","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-090129","anchor_url":"https://secwatch.observer/filing/0001213900-25-090129#claim-8e4ac9287592b8215defdd83dbcf7b87f49134e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390025090129/0001213900-25-090129-index.htm"},{"fact_type":"earnings_release","fact_key":"d0f8677ec81147100c8b318eb312b3a8173bd520","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-04-25T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter 2024","report_date":"2024-04-25","result_type":"reported_results","revenue_text":null},"claim":"Oruka Therapeutics, Inc. reported financial results for first quarter 2024.","evidence_excerpt":"ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-048364","anchor_url":"https://secwatch.observer/filing/0000950170-24-048364#claim-d0f8677ec81147100c8b318eb312b3a8173bd520","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024048364/0000950170-24-048364-index.htm"},{"fact_type":"executive_change","fact_key":"792d60f292","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-04-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-04-03","interim":true,"role":"President and principal executive officer","role_category":"president","successor_name":null,"successor_named":false},"claim":"Thomas A. Keuer was appointed as President and principal executive officer at Oruka Therapeutics, Inc..","evidence_excerpt":"the Board appointed Thomas A. Keuer, the Company’s Chief Operating Officer, to serve as ARCA’s President and principal executive officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-041846","anchor_url":"https://secwatch.observer/filing/0000950170-24-041846#claim-792d60f292","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/0000950170-24-041846-index.htm"},{"fact_type":"executive_change","fact_key":"eace0071e6","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-04-04T23:59:59+00:00","payload":{"action":"concluded employment and service as director","action_category":"departure","departure_tone":"routine","effective_date":"2024-04-03","interim":false,"role":"President, Chief Executive Officer and Director","role_category":"ceo","successor_name":"Thomas A. Keuer","successor_named":true},"claim":"Michael Bristow departed as President, Chief Executive Officer and Director at Oruka Therapeutics, Inc..","evidence_excerpt":"Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors (the “Board”) of ARCA have mutually agreed to conclude Dr. Bristow’s employment and service as a director, effective April 3, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-041846","anchor_url":"https://secwatch.observer/filing/0000950170-24-041846#claim-eace0071e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/0000950170-24-041846-index.htm"},{"fact_type":"material_agreement","fact_key":"41e097b74e7ddd52e025dd1e672ed29a001713e1","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-04-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger and Reorganization","agreement_type":"merger","counterparty":"ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II LLC, and Oruka Therapeutics, Inc.","effective_date":"2024-04-03","item_codes_triggered":["1.01"],"value_text":null},"claim":"Oruka Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II LLC, and Oruka Therapeutics, Inc. (effective 2024-04-03).","evidence_excerpt":"On April 3, 2024, ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), Atlas Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of ARCA (“ Merger Sub I ”), Atlas Merger Sub II LLC, a Delaware limited liability company and a wholly-owned subsidiary of ARCA (“ Merger Sub II ”) and Oruka Therapeutics, Inc., a Delaware corporation (“ Oruka ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-085437","anchor_url":"https://secwatch.observer/filing/0001193125-24-085437#claim-41e097b74e7ddd52e025dd1e672ed29a001713e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/0001193125-24-085437-index.htm"},{"fact_type":"material_agreement","fact_key":"7e46ceb22a3a0f4f3cc8ad6e6dee0c164fad24f3","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-03-22T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"First Amendment to Office Lease Agreement","agreement_type":"lease","counterparty":"Lotus Church Ranch, LLC","effective_date":"2024-03-19","item_codes_triggered":["1.01"],"value_text":"$8,206.42"},"claim":"Oruka Therapeutics, Inc. amended First Amendment to Office Lease Agreement with Lotus Church Ranch, LLC valued at $8,206.42 (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, ARCA biopharma, Inc., a Delaware corporation (“ARCA”), entered into the First Amendment to Office Lease Agreement (the “Lease Amendment”) with Lotus Church Ranch, LLC (the “Landlord”), which amended that certain Office Lease Agreement, dated as of August 7, 2020, related to the Company’s headquarters in Westminster, Colorado (the “Lease”). Under the Lease Amendment, the term of the Lease was extended an additional six (6) months through September 30, 2024 (the “Lease Extension”). Commencing on April 1, 2024, the minimum monthly rent shall be increased to $8,206.42.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-035373","anchor_url":"https://secwatch.observer/filing/0000950170-24-035373#claim-7e46ceb22a3a0f4f3cc8ad6e6dee0c164fad24f3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024035373/0000950170-24-035373-index.htm"},{"fact_type":"executive_change","fact_key":"f50e76f0b6","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-02-06T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-02","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dan Mitchell resigned as director at Oruka Therapeutics, Inc..","evidence_excerpt":"On February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors (the “ Board ”) of ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-011737","anchor_url":"https://secwatch.observer/filing/0000950170-24-011737#claim-f50e76f0b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024011737/0000950170-24-011737-index.htm"},{"fact_type":"executive_change","fact_key":"12681d6e02","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-02-06T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-02","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Raymond L. Woosley resigned as director at Oruka Therapeutics, Inc..","evidence_excerpt":"On February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors (the “ Board ”) of ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-011737","anchor_url":"https://secwatch.observer/filing/0000950170-24-011737#claim-12681d6e02","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024011737/0000950170-24-011737-index.htm"},{"fact_type":"earnings_release","fact_key":"e8d5ac4b2a7759a6150937bc850cb21bef8d692a","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-02-01T23:59:59+00:00","payload":{"eps_text":"$0.37 per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the year ended December 31, 2023 was $5.3 million, or $0.37 per basic and diluted share","period_text":"the year ended December 31, 2023","report_date":"2024-02-01","result_type":"reported_results","revenue_text":null},"claim":"Oruka Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $5.3 million, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share.","evidence_excerpt":"Net loss for the year ended December 31, 2023 was $5.3 million, or $0.37 per basic and diluted share, compared to $9.9 million, or $0.69 per basic and diluted share in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-009852","anchor_url":"https://secwatch.observer/filing/0000950170-24-009852#claim-e8d5ac4b2a7759a6150937bc850cb21bef8d692a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009852/0000950170-24-009852-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8d79505b7497c5936397f5ac3345bd1dda25fd9e","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-01-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-30","outcome":"passed","proposal_text":"Advisory vote on the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,577,852","subject":null,"votes_abstain":"19,941","votes_against":"1,472,454","votes_for":"6,548,473","votes_withheld":null}]},"claim":"Oruka Therapeutics, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2024-01-30 meeting.","evidence_excerpt":"For Against Abstentions Broker Non-Votes 6,548,473 1,472,454 19,941 2,577,852","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-009397","anchor_url":"https://secwatch.observer/filing/0000950170-24-009397#claim-8d79505b7497c5936397f5ac3345bd1dda25fd9e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e18b13f0c0e4f063cb1692ca6db02e260425a736","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-01-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-30","outcome":"passed","proposal_text":"Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"68,141","votes_against":"263,929","votes_for":"10,286,650","votes_withheld":null}]},"claim":"Oruka Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2024-01-30 meeting.","evidence_excerpt":"For Against Abstentions Broker Non-Votes 10,286,650 263,929 68,141 —","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-009397","anchor_url":"https://secwatch.observer/filing/0000950170-24-009397#claim-e18b13f0c0e4f063cb1692ca6db02e260425a736","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6dd3fec05ee6c2755220b934f7ebff1e9034a235","cik":907654,"ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-01-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-30","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"2,577,852","subject":"Dr. Michael R. Bristow","votes_abstain":null,"votes_against":null,"votes_for":"6,952,545","votes_withheld":"1,088,323"},{"broker_non_votes":"2,577,852","subject":"Mr. Robert E. Conway","votes_abstain":null,"votes_against":null,"votes_for":"6,758,409","votes_withheld":"1,282,459"}]},"claim":"Oruka Therapeutics, Inc. shareholders approved Election of Directors at the 2024-01-30 meeting.","evidence_excerpt":"Nominee For Withheld Broker Non-Votes Dr. Michael R. Bristow 6,952,545 1,088,323 2,577,852 Mr. Robert E. Conway 6,758,409 1,282,459 2,577,852","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-009397","anchor_url":"https://secwatch.observer/filing/0000950170-24-009397#claim-6dd3fec05ee6c2755220b934f7ebff1e9034a235","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm"}]}